{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T01:03:56Z","timestamp":1779757436805,"version":"3.53.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jid.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:43:33Z","timestamp":1765903413000},"page":"1678-1681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers to comparison of relative remission rates of systemic therapies for moderate-to-severe plaque psoriasis"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-0872","authenticated-orcid":false,"given":"Eliza J.","family":"Dewey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.12.003_bib1","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/jdv.18477","article-title":"Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis Foundation","volume":"36","author":"Balak","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2019.01.035","article-title":"Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8-year multicenter study","volume":"88","author":"Chiu","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.12.003_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archderm.141.1.82","article-title":"Definitions of measures of effect duration for psoriasis treatments","volume":"141","author":"Gordon","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2025.12.003_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.12.003_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40257-024-00887-8","article-title":"Predicting the time to relapse following withdrawal from different biologics in patients with psoriasis who responded to therapy: a 12-year multicenter cohort study","volume":"25","author":"Huang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2025.12.003_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/247553031016a00205","article-title":"How long does the benefit of biologics last? An update on time to relapse and potential for rebound of biologic agents for psoriasis","volume":"16","author":"Kamaria","year":"2010","journal-title":"Psoriasis Forum"},{"key":"10.1016\/j.jid.2025.12.003_bib7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/bjd.12583","article-title":"The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials","volume":"169","author":"Langley","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.003_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2340\/00015555756569","article-title":"Remission of ordinary psoriasis following a short clearance course of cyclosporin","volume":"75","author":"Levell","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","article-title":"Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review","volume":"23","author":"Masson Regnault","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2025.12.003_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100116","article-title":"The relapse of psoriasis: mechanisms and mysteries","volume":"2","author":"Tian","year":"2022","journal-title":"JID Innov"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2503667X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2503667X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:49:49Z","timestamp":1779756589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X2503667X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022202X2503667X"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.12.003","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to comparison of relative remission rates of systemic therapies for moderate-to-severe plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}